BY ALEXANDRE STIPANOVICH 09.23.25
SSRIs and classic psychedelics (LSD, psilocybin, DMT) rely on serotonin, but with starkly different timelines: SSRIs through gradual serotonin 1A receptors (5-HT1AR)–linked adaptations over weeks, while Psychedelics through acute serotonin 2A receptors (5-HT2AR) agonism that rapidly induces plasticity and hallucinations.
Against this dichotomy stands a singular exception—5-MeO-DMT, the only known psychedelic that potently and efficaciously activates both 5-HT2AR and 5-HT1AR. This dual action yields a profile distinct from either SSRIs or classic psychedelics: no kaleidoscopic visions, yet profound states of dissolution, unity, and relief, coupled with robust antidepressant effects.
DMT itself, like psilocybin or LSD, is a prototypical 5-HT2AR agonist—driving cortical disintegration, glutamatergic surges, and the vivid hallucinations that define the psychedelic state. 5-MeO-DMT, though structurally related, uniquely activates strongly 5-HT1AR as well. This receptor duality sets it apart: no other classic psychedelic combines such strong 5-HT2AR and 5-HT1AR engagement in this way.
The 5-HT2AR activity of 5-MeO-DMT still opens the door to neuroplasticity: spinogenesis, dendritic growth, and network reorganization that underlie durable antidepressant benefit after a single acute administration. The difference lies in how 5-HT1AR alters the experiential and neural landscape.
Activation of 5-HT1AR—both autoreceptors in the raphe nuclei and postsynaptic receptors in the prefrontal cortex—dampens serotonergic firing and downstream glutamate release. This dampening curtails the excitatory cascades normally triggered by unopposed 5-HT2AR stimulation. In other words, 5-HT1AR activity prevents the sensory amplification and cortical hyper-excitation that generate hallucinations. Instead of outward projections and visual distortions, the subject is carried inward, into silence and dissolution.
“5-MeO-DMT may demonstrate that bliss is not produced by added content, but by the removal of distortion: a state only possible when excitation and inhibition are held in precise balance.”
This receptor duet explains the paradox of 5-MeO-DMT: extreme intensity, yet minimal imagery. Users describe annihilation of ego, immersion in “pure awareness,” and a blissful release of self—states that feel less like hallucination than like transcendence. Crucially, this occurs alongside rapid structural remodeling, pointing toward a therapeutic profile that combines the immediacy of psychedelics with the tolerability of non-hallucinogenic agents.
For psychiatry, 5-MeO-DMT may be a blueprint. Its ability to induce antidepressant plasticity in a single session, while avoiding destabilizing hallucinations, suggests a path forward for drug developers: compounds tuned to preserve 5-HT2AR–driven plasticity but modulated by 5-HT1AR to temper perceptual distortion. 5-MeO-DMT is therefore not only unique among psychedelics, but also highly promising as a therapeutic model—an agent that opens the brain to change while guiding the mind into calm, unity, and healing.
One of the most striking aspects of 5-MeO-DMT is that users do not simply avoid hallucinations; they often enter states of “pure awareness,” described as vast, silent, and ego-free. Why should this state be blissful rather than neutral or frightening? A plausible answer lies in the compound’s dual receptor balance. 5-HT2AR activation destabilizes entrenched cortical patterns, loosening rigid self-models. At the same time, 5-HT1AR activation stabilizes serotonergic tone and suppresses glutamatergic overdrive, preventing sensory chaos. What remains is a bare field of awareness, undistorted, but open. The brain, released from both self-clinging and perceptual overload, may register this equilibrium as bliss. In this sense, 5-MeO-DMT may demonstrate that bliss is not produced by added content, but by the removal of distortion: a state only possible when excitation and inhibition are held in precise balance.
References
- Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. doi:10.1124/pr.115.011478
- Halberstadt, A. L., & Geyer, M. A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364–381. doi:10.1016/j.neuropharm.2011.01.017
- Shen, H.-W., Jiang, X.-L., Winter, J. C., & Yu, A.-M. (2010). Psychedelic 5-MeO-DMT: Metabolism, pharmacokinetics, and pharmacological actions. Current Drug Metabolism, 11(8), 659–666. doi:10.2174/138920010794233495
- Riga MS, Lladó-Pelfort L, Artigas F, Celada P. The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: regionally-selective involvement of 5-HT1AR and 5-HT2AR. Neuropharmacology. 2018;142:219–230. doi:10.1016/j.neuropharm.2017.11.049.
